Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT07020819 | An Open Label Clinical Study to Evaluate Tanruprubart (Also Commonly Known as ANX005) in Participants With Guillain-Barré Syndrome (FORWARD Study) | PHASE3 | RECRUITING | 30 | — | — | Sep 12, 2025 | Jun 30, 2028 | May 28, 2026 | 13 | United States, Denmark |
| Arm | Type | Description |
|---|---|---|
| Tanruprubart | EXPERIMENTAL | Participants will receive a single 30 mg/kg intravenous (IV) infusion of tanruprubart on Day 1. |
| Name | Type | Description |
|---|---|---|
| Tanruprubart | DRUG | Solution for IV infusion. |
Key Inclusion Criteria: * Diagnosis of GBS according to the National Institute of Neurological Disorders and Stroke Diagnostic Criteria for GBS. * Onset of GBS-related weakness ≤10 days before start of infusion on Day 1 * GBS-disability score (DS) score of 3, 4, or 5 at screening and before start o...